Edgewise Therapeutics (EWTX) Non Operating Income (2024 - 2025)
Edgewise Therapeutics (EWTX) reported Non Operating Income of $6.2 million for Q3 2025, down 1.76% on a YoY basis from $6.3 million in Q3 2024, and down 4.67% sequentially from $6.5 million in Q2 2025.
Edgewise Therapeutics (EWTX) Non Operating Income (2024 - 2025) Analysis & Trends
Edgewise Therapeutics (EWTX) has 2 years of Non Operating Income data on file, last reported at $6.2 million in Q3 2025.
- For the quarter ending Q3 2025, Non Operating Income fell 1.76% year-over-year to $6.2 million; the trailing twelve-month figure through Sep 2025 stood at $23.7 million (changed N/A YoY), and the FY2024 full-year result was $25.0 million, up 76.26% from the prior year.
- Non Operating Income fell to $6.2 million in Q3 2025, from $6.5 million in the prior quarter.
- In the past five years, Non Operating Income ranged from a high of $6.6 million in Q2 2024 to a low of $5.2 million in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -9.22 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 188.30 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | 5.75 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -8.59 Mn |
| 10 | Edgewise Therapeutics | 4.21 Bn | 4.21 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 6.19 Mn |
| Jun 30, 2025 | 6.50 Mn |
| Mar 31, 2025 | 5.16 Mn |
| Dec 31, 2024 | 5.88 Mn |
| Sep 30, 2024 | 6.30 Mn |
| Jun 30, 2024 | 6.61 Mn |
| Mar 31, 2024 | 6.23 Mn |